Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.74 |
| ▸ | IDO1 | P14902 | 7/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | NOS3 | P29474 | 5/20 | 0.57 |
| ▸ | NOS1 | P29475 | 5/20 | 0.57 |
| ▸ | NOS2 | P35228 | 5/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29670895 | 1.00 | KMO (0.74) | KMOIDO1KMT2AMEN1NOS3 | |
| SCHEMBL2978251 | 0.88 | PIK3CB (0.58) | KMOIDO1KMT2AMEN1HSD17B10 | |
| SCHEMBL4427326 | 0.87 | IDO1 (0.71) | KMOIDO1KMT2AMEN1NOS3 | |
| SCHEMBL29958110 | 0.87 | IDO1 (0.71) | KMOIDO1KMT2AMEN1NOS3 | |
| SCHEMBL16823385 | 0.85 | KMO (1.00) | KMOIDO1KMT2AMEN1TMEM97 | |
| SCHEMBL4425116 | 0.83 | KMT2A (0.66) | KMOIDO1KMT2AMEN1NOS3 | |
| SCHEMBL5416540 | 0.82 | CBX7 (0.62) | KMOIDO1KMT2AMEN1 | |
| SCHEMBL5289472 | 0.82 | MIF (0.63) | KMOKMT2AMEN1ALDH1A1 | |
| SCHEMBL30660242 | 0.82 | CBX7 (0.62) | KMOIDO1KMT2AMEN1 | |
| SCHEMBL11134988 | 0.81 | KMO (0.81) | KMOIDO1KMT2AMEN1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308228-A1 | PLASMA KALLIKREIN INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-10426784-B2 | Imidazodiazepine compound | ASTELLAS PHARMA INC. (JP) | 2019-10-01 | — | — | US | disclosed |
| EP-3312181-B1 | IMIDAZODIAZEPINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-20180185383-A1 | IMIDAZODIAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2018-07-05 | — | — | US | disclosed |
| EP-3312181-A1 | IMIDAZODIAZEPINE COMPOUND | Astellas Pharma Inc. (JP) | 2018-04-25 | — | — | EP | disclosed |
| EP-2987793-B1 | HETEROCYCLIC ACETIC ACID AMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-10-25 | — | — | EP | disclosed |
| US-9708307-B2 | Heterocyclic acetamide compound | ASTELLAS PHARMA INC. (JP) | 2017-07-18 | — | — | US | disclosed |
| US-9708307-B2 | Heterocyclic acetamide compound | ASTELLAS PHARMA INC. (JP) | 2017-07-18 | — | — | US | disclosed |
| US-9708307-B2 | Heterocyclic acetamide compound | ASTELLAS PHARMA INC. (JP) | 2017-07-18 | — | — | US | disclosed |
| EP-2987793-A1 | HETEROCYCLIC ACETIC ACID AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2016-02-24 | — | — | EP | disclosed |
| WO-2008011551-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011551-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021023-A1 | 4'-[(1R)-1-[[(6,7-dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin- 4-yl)acetyl](methyl)amino]-2-(4-morpholinyl)ethyl]-4-biphenylcarboxylic acid; as antagonists of urotensin II, congestive heart failure, stroke, ischemic heart disease (e.g. angina, myocardial ischemia), cardiac arrhythmia, hypertension | GLAXOSMITHKLINE LLC | 2008-01-24 | — | — | US | disclosed |
| US-20080021023-A1 | 4'-[(1R)-1-[[(6,7-dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin- 4-yl)acetyl](methyl)amino]-2-(4-morpholinyl)ethyl]-4-biphenylcarboxylic acid; as antagonists of urotensin II, congestive heart failure, stroke, ischemic heart disease (e.g. angina, myocardial ischemia), cardiac arrhythmia, hypertension | GLAXOSMITHKLINE LLC | 2008-01-24 | — | — | US | disclosed |
| US-20070191447-A1 | Novel heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1719761-A1 | NOVEL HETEROCYCLIC COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-4438126-A | Lower alkanoic acid derivatives of 2-oxo-benzoxazolines and aldose reductase inhibiting compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-03-20 | — | — | US | disclosed |
| EP-0022317-B1 | 2-OXO-BENZOTHIAZOLINE, BENZOXAZOLINE OR INDOLINE DERIVATIVES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-09-21 | — | — | EP | disclosed |
| US-4370340-A | ANTIDIABETIC AGENT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-01-25 | — | — | US | disclosed |
| EP-0022317-A1 | 2-Oxo-benzothiazoline, benzoxazoline or indoline derivatives, their preparation, and pharmaceutical compositions comprising such derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185383-A1 | IMIDAZODIAZEPINE COMPOUND | HTR1D, DRD2, DRD1 | KMO 1319/4885IDO1 343/4885KMT2A 1465/4885 |
| US-20070191447-A1 | Novel heterocyclic compound | OPRD1, GRIN3A, GRM3 | KMO 1091/4885IDO1 1932/4885KMT2A 2049/4885 |
| US-10426784-B2 | Imidazodiazepine compound | GRIN2D, HTR1D, DRD2 | KMO 1611/4885IDO1 595/4885KMT2A 1108/4885 |
| US-20080021023-A1 | 4'-[(1R)-1-[[(6,7-dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin- 4-yl)acetyl](methyl)amino]-2-(4-morpholinyl)ethyl]-4-biphenylcarboxylic acid; as antagonists of urotensin II, congestive heart failure, stroke, ischemic heart disease (e.g. angina, myocardial ischemia), cardiac arrhythmia, hypertension | UTS2R, PLAUR, FABP3 | KMO 3437/4885IDO1 837/4885KMT2A 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.